About this trial
The goal of this study is to evaluate the effectiveness and implementation of a dyadic management of the Chronic Disease Self-Management Program (CDSMP) for older adults with co-occurring cognitive impairment and diabetes with the involvement of caregivers.
The main questions it aims to answer are:
* Does the intervention improve diabetes self-management and cognitive function in older adults? * How is the implementation of the intervention in real-world settings?
Participants will:
* Attend weekly CDSMP session over a 6-week period (2.5-hour per session). * Provide feedback on their experience with the intervention through interviews and surveys.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Individuals with DM aged >= 55 years old;
Recent glycosylated haemoglobin (HbA1c) level of 6.5% or above without change in diabetes medication within the last 3 months based on centre's records;
Subjective cognitive decline (using SCDQ21) (separately reported by the patient and/or caregiver) and confirmed by MOCA (Chinese version) screened by the research nurses;
Subjects with nominated primary caregivers will be recruited in the intervention group;
Disqualifiers
Medical diagnoses of dementia;
Those who have terminal illness;
For caregivers: those who are temporary caregivers and have only provided/involved in care for less than a year.
Trial design
Parallel
Treatments tested in this trial
CDSMP + caregiver support
BehavioralThe CDSMP is an evidence-based program consisting of 2.5-hour sessions held weekly over a six-week period, delivered by two trained leaders per session in person.
Usual Care
BehavioralUsual care (diabetes education, glucose monitoring and medical consultation)
Treatment groups
Trial outcomes
Primary outcomes
Self-Care of Diabetes Index
Self-Care of Diabetes Index (SCODI) is a scale, scoring from 0 to 100, where higher scores indicate better self-care for diabetes.
Secondary outcomes
Glycated hemoglobin (HbA1c)
Glycated hemoglobin (HbA1c) measures average blood sugar levels over the past 2-3 months, acting as a crucial diagnostic and management tool for diabetes. A level below 7% is recommended for patients with diabetes.
Subjective Cognitive Decline Questionnaire 21
Subjective Cognitive Decline Questionnaire 21 (SCD-Q21) is a reliable, validated 21-item tool designed to detect self-reported cognitive changes, helping distinguish Mild Cognitive Impairment (MCI) from healthy people. The score is from 0 to 21, with a higher score corresponding to a greater likelihood of MCI.
Montreal Cognitive Assessment
Montreal Cognitive Assessment (MoCA) is a widely used screening scale designed to detect mild cognitive impairment, with scores from 0 to a maximum of 30 points. A higher score on MoCA indicates better cognitive function and less impairment.
Caregiver Contribution to Self-Care of Diabetes Inventory
Caregiver Contribution to Self-Care of Diabetes Inventory (CC-SCODI) is a validated scale measuring caregiver efforts in diabetes maintenance, monitoring, and management. The score is from 0 to 100 points, with a higher score indicating higher caregiver involvement.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: